In-Depth Analysis of the Emerging Targeted Protein Degradation (TPD) Space, 2023 Research Report - Opportunities in Research and Product Development Partnerships to Develop Next-gen TPD Therapeutics - ResearchAndMarkets.com
This insightful research report delves into the burgeoning field of targeted protein degradation (TPD), a promising approach for treating previously untreatable diseases by precisely targeting disease-causing proteins, minimizing potential side effects.
It provides an extensive analysis of various TPD strategies, including extracellular and intracellular protein degraders, their applicability across diseases, key players in clinical translation, and identifies four transformative growth opportunities in the TPD market.
With approximately 80% of a cell's proteome resistant to conventional treatments, TPD has emerged as a crucial advancement, with PROTACs as a prominent protein degrader.
This report explores the development of intracellular and extracellular degraders, addressing the limitations of each. Furthermore, it highlights the role of increased private and public funding in propelling the growth of TPD technology, offering valuable insights into funding trends within the TPD space.
Questions that this report seeks to answer include:
What are the key drivers or challenges for TPD development?
How do the private funding and partnership landscapes look for TPD?
Who are the key industry participants developing targeted protein degraders?
What are the R&D trends emerging across TPD that could further shape the development of protein degraders?
Key Topics Covered:
1 Strategic Imperatives
Why Is It Increasingly Difficult to Grow?
The Strategic Imperative
The Impact of the Top 3 Strategic Imperatives on the Targeted Protein Degradation Industry
Growth Opportunities Fuel the Growth Pipeline Engine
2 Growth Opportunity Analysis
Growth Driver Analysis
Growth Restraints Analysis
Scope of Analysis
The Need for Targeted Protein Degraders
3 R&D and Innovation Ecosystem
TPD - Evolution and Clinical aspect
Intracellular Targeted Protein Degraders in Clinical Development
Intracellular Targeted Protein Degraders - PROTACs
Emerging Intracellular Targeted Protein Degraders
Innovation Spotlight - Intracellular Protein Degradation
Development of Extracellular Protein Degradation Therapeutics
Challenges for Extracellular Protein Degrader Development
Extracellular Protein Degradation Approaches
Emerging Classes of Extracellular Protein Degraders
Innovation Spotlight - Extracellular Protein Degradation
Key Differences Between Extracellular and Intracellular Protein Targeting
Targeted Protein Degradation Technology Snapshot
4 R&D Focus and Application Landscape
R&D Innovation Trends
Protein Degraders in Healthcare and Beyond
Protein Degraders across Different Disease Areas
Key Players and Therapeutics Areas of Focus
Protein Degraders Innovation Landscape
5 Market Dynamics
Public and Private Funding for TPD Therapy Development
Partnership Landscape of Biopharma Companies in TPD Therapeutics Development
TPD Companies' Partnerships for Developing TPD Therapeutics
6 Growth Opportunity Universe
Growth Opportunity 1: Efficient and Tissue-specific Degrader Delivery
Growth Opportunity 2: Novel E3 Ligases Discovery and Design
Growth Opportunity 3: Advanced PROTACs Development
Growth Opportunity 4: Research and Product Development Partnerships to Develop Next-gen TPD Therapeutics
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
The global biochips market size is estimated to grow by USD 43.27 billion from 2022 to 2027, according to Technavio. The market is estimated to grow at a CAGR of 25.15% during the forecast period. North America is estimated to account for 41% of the...
ITAAN Pharma and ACIC Pharmaceuticals join forces in a strategic venture to advance generic injectables for the North American market. The collaboration is for enhanced product development and manufacturing excellence, resulting in a comprehensive...
UE Systems, a pioneering force in developing ultrasonic detection instruments and solutions for maintenance and reliability, unveils its latest innovation ? the OnTrak Wireless system. This cutting-edge solution transcends traditional bearing health...
In Q2 2023, Amador Bioscience, a next generation CRO focusing on translational science and early clinical development, announced the addition of Dr. Lorin Roskos to the Board of Directors. Dr. Roskos has also taken on the roles of Chief Scientific...
--The Phase III clinical trial of ASC40 for moderate to severe acne vulgaris will enroll 480 subjects
--The protocol of Phase III clinical trial has been agreed by Center for Drug Evaluation, National Medical Products Administration and obtained the...